Acquired resistance of Mycobacterium tuberculosis to bedaquiline

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Andries, Koen ^a   Villellas, Cristina ^a   Coeck, Nele ^b   Thys, Kim ^a   Gevers, Tom ^a   Vranckx, Luc ^a   Lounis, Nacer ^a   De Jong, Bouke C ^b   Koul, Anil ^a  

^a Department of Infectious Diseases Janssen Pharmaceutica ^*  (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; RESERPINE; VERAPAMIL; BACTERIAL PROTEIN; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERICIDAL ACTIVITY; CROSS RESISTANCE; DRUG ANTAGONISM; DRUG EFFICACY; GENE MUTATION; GENETIC CODE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL GENE; BIOLOGICAL MODEL; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR GENETICS; MOUSE; MUTATION; REPRODUCTIVE FITNESS; TUBERCULOSIS; UPREGULATION;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BASE SEQUENCE; CLOFAZIMINE; DIARYLQUINOLINES; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; GENETIC FITNESS; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTATION; MYCOBACTERIUM TUBERCULOSIS; RESERPINE; TUBERCULOSIS; UP-REGULATION; VERAPAMIL;

EID: 84904255286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102135     Document Type: Article

References (24)

1. Cohen J (2013) Infectious disease. Approval of novel TB drug celebrated - with restraint. Science 339: 130.
2. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227. (Pubitemid 40116230)
3. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, et al. (2010) Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 54: 1022-1028.
4. Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S (2012) New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother 56: 2326-2334.
5. Hartkoorn RC, Uplekar S, Cole ST (2014) Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58: 2979-2981.
6. Camacho LR, Constant P, Raynaud C, Laneelle MA, Triccas JA, et al. (2001) Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. J Biol Chem 276: 19845-19854.
7. Milano A, Pasca MR, Provvedi R, Lucarelli AP, Manina G, et al. (2009) Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb) 89: 84-90.
8. Ioerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, et al. (2013) Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One 8: e75245.
9. Domenech P, Reed MB, Barry CE 3rd (2005) Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun 73: 3492-3501. (Pubitemid 40745893)
10. DasGupta SK, Jain S, Kaushal D, Tyagi AK (1998) Expression systems for study of mycobacterial gene regulation and development of recombinant BCG vaccines. Biochem Biophys Res Commun 246: 797-804. (Pubitemid 28420938)
11. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, et al. (2014) Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58: 574-576.
12. da Silva PE, Von Groll A, Martin A, Palomino JC (2011) Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 63: 1-9.
13. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, et al. (2011) Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 184: 269-276.
14. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, et al. (2013) Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med 188: 600-607.
15. Lamichhane G, Tyagi S, Bishai WR (2005) Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs. Infect Immun 73: 2533-2540. (Pubitemid 40470857)
16. Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, et al. (2012) The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 56: 4806-4815.
17. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, et al. (2012) Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56: 3114-3120.
18. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36: D901-906. (Pubitemid 351149842)
19. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, et al. (2012) Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 56: 3271-3276.
20. de Steenwinkel JE, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, et al. (2010) Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother 65: 2582-2589.
21. Koul A, Vranckx L, Dhar N, Gohlmann HW, Ozdemir E, et al. (2014) Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun 5: 3369.
22. Palomino JC, Martin A, Camacho M, Guerra H, Swings J, et al. (2002) Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 46: 2720-2722. (Pubitemid 34793497)
23. Cole ST, Barrell BG (1998) Analysis of the genome of Mycobacterium tuberculosis H37Rv. Novartis Found Symp 217: 160-172; discussion 172-167.
24. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, et al. (2007) Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 3: 323-324. (Pubitemid 46789271)